Document is current
Any future updates will be listed below
-
Authors
Young, Kira A.
Hosseini, Mohsen https://orcid.org/0000-0002-1686-8512
Mistry, Jayna J.
Morganti, Claudia
Mills, Taylor S.
Cai, Xiurong
James, Brandon T. https://orcid.org/0000-0002-1824-747X
Nye, Griffin J.
Fournier, Natalie R.
Voisin, Veronique
Chegini, Ali https://orcid.org/0009-0007-8249-7258
Schimmer, Aaron D. https://orcid.org/0000-0003-4023-3899
Bader, Gary D. https://orcid.org/0000-0003-0185-8861
Egan, Grace https://orcid.org/0000-0002-4036-8403
Mansour, Marc R. https://orcid.org/0000-0001-6835-3791
Challen, Grant A. https://orcid.org/0000-0003-4669-8814
Pietras, Eric M. https://orcid.org/0000-0002-7339-8828
Fisher-Wellman, Kelsey H.
Ito, Keisuke https://orcid.org/0000-0002-6702-9735
Chan, Steven M. https://orcid.org/0000-0002-4354-0731
Trowbridge, Jennifer J. https://orcid.org/0000-0002-7636-9504
-
Funding
Funding for this research was provided by:
U.S. Department of Health & Human Services | NIH | National Institute of Diabetes and Digestive and Kidney Diseases (R01DK118072, R56DK118072, R01DK119394, R01DK098263, R01DK124883)
U.S. Department of Health & Human Services | NIH | National Institute on Aging (R01AG069010, U01AG077925)
U.S. Department of Health & Human Services | NIH | National Cancer Institute (P30CA034196)
Edward P. Evans Foundation
Leukemia and Lymphoma Society
National Science Foundation
Cleo Meador and George R. Scott Endowed Chair
U.S. Department of Health & Human Services | NIH | National Heart, Lung, and Blood Institute (R01HL148852)
- License Information
-
More Information
Article History
Received: 13 January 2025
Accepted: 14 February 2025
First Online: 16 April 2025
Competing interests
: A.D.S. has received research funding from Takeda Pharmaceuticals, BMS and Medivir AB, and consulting fees/honorarium from Takeda, Novartis, Jazz, and Otsuka Pharmaceuticals. A.D.S. is named on a patent application for the use of DNT cells to treat AML. A.D.S. is a member of the Medical and Scientific Advisory Board of the Leukemia and Lymphoma Society of Canada. S.M.C. has received research funding from the Centre for Oncology and Immunology in Hong Kong, Celgene/BMS, AbbVie Pharmaceuticals, Agios Pharmaceuticals, and Servier Laboratories. M.R.M. is on the Scientific Advisory Board for Peptone and performed consultancy for Nuage Therapeutics. G.A.C. has performed consulting and received research funding from Incyte, Ajax Therapeutics and ReNAgade Therapeutics Management, and is a co-founder, member of the scientific advisory board and shareholder of Pairidex, Inc. J.J.T. has received research funding from H3 Biomedicine, Inc and patent royalties from Fate Therapeutics. The remaining authors declare no competing financial interests.
